AIM:AGL

Stock Analysis Report

Executive Summary

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products.


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has ANGLE's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AGL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.0%

AGL

2.1%

GB Medical Equipment

1.7%

GB Market


1 Year Return

-22.0%

AGL

1.3%

GB Medical Equipment

-21.8%

GB Market

Return vs Industry: AGL underperformed the UK Medical Equipment industry which returned -0.3% over the past year.

Return vs Market: AGL exceeded the UK Market which returned -23.6% over the past year.


Shareholder returns

AGLIndustryMarket
7 Day1.0%2.1%1.7%
30 Day-20.8%-8.9%-12.0%
90 Day-21.4%-17.6%-25.3%
1 Year-22.0%-22.0%3.3%1.3%-17.9%-21.8%
3 Year-2.4%-2.4%5.5%-0.7%-11.8%-22.8%
5 Year-34.0%-34.0%38.1%25.0%0.1%-22.4%

Price Volatility Vs. Market

How volatile is ANGLE's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ANGLE undervalued compared to its fair value and its price relative to the market?

2.85x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AGL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AGL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AGL is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: AGL is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AGL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AGL is overvalued based on its PB Ratio (2.9x) compared to the GB Medical Equipment industry average (2.8x).


Next Steps

Future Growth

How is ANGLE forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

2.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AGL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AGL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AGL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AGL's revenue (94.4% per year) is forecast to grow faster than the UK market (2.5% per year).

High Growth Revenue: AGL's revenue (94.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AGL's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has ANGLE performed over the past 5 years?

-21.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AGL is currently unprofitable.

Growing Profit Margin: AGL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AGL is unprofitable, and losses have increased over the past 5 years at a rate of -21.2% per year.

Accelerating Growth: Unable to compare AGL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AGL is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-9.5%).


Return on Equity

High ROE: AGL has a negative Return on Equity (-32.19%), as it is currently unprofitable.


Next Steps

Financial Health

How is ANGLE's financial position?


Financial Position Analysis

Short Term Liabilities: AGL's short term assets (£24.9M) exceed its short term liabilities (£2.1M).

Long Term Liabilities: AGL's short term assets (£24.9M) exceed its long term liabilities (£1.5M).


Debt to Equity History and Analysis

Debt Level: AGL is debt free.

Reducing Debt: AGL had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AGL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AGL has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of -23.8% each year.


Next Steps

Dividend

What is ANGLE's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AGL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AGL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AGL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AGL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AGL's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Andrew David Newland (57yo)

no data

Tenure

UK£403,000

Compensation

Mr. Andrew David William Newland, Meng, ACA founded ANGLE Plc in 1994 and serves as its Group Chief Executive. Mr. Newland founded Provexis, the first ever spin-out of Rowett Institute, Europe’s leading nu ...


CEO Compensation Analysis

Compensation vs Market: Andrew David's total compensation ($USD497.49K) is above average for companies of similar size in the UK market ($USD335.16K).

Compensation vs Earnings: Andrew David's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Andrew David Newland
Founderno dataUK£403.00k4.09% £3.6m
Ian Griffiths
CFO, Finance Director16.08yrsUK£258.00k0.39% £347.0k
Paul Smith
VP & Chief Executive Officer of ANGLE Biosciences Inc2.42yrsno datano data
Martin Cooke
Director of Manufacturing & Regulatory Affairs2.25yrsno datano data
Michael O'Brien
Business Development Director6.42yrsno datano data

2.6yrs

Average Tenure

54yo

Average Age

Experienced Management: AGL's management team is considered experienced (2.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Andrew David Newland
Founderno dataUK£403.00k4.09% £3.6m
Ian Griffiths
CFO, Finance Director16.08yrsUK£258.00k0.39% £347.0k
Harold Swerdlow
Member of Scientific Advisory Boardno datano datano data
Garth Selvey
Non-Executive Chairman12.58yrsUK£23.00k0.012% £10.3k
Ashok Venkitaraman
Member of Scientific Advisory Boardno datano datano data
Brian Howlett
Non- Executive & Senior Independent Director1.25yrsUK£23.00k0.0058% £5.1k
Clive Stanway
Member of Scientific Advisory Boardno datano datano data
Adrian Newland
Member of Scientific Advisory Boardno datano datano data
George Hvichia
Member of Scientific Advisory Board2.25yrsno datano data
James Reuben
Member of Scientific Advisory Board4.83yrsno datano data

8.7yrs

Average Tenure

57yo

Average Age

Experienced Board: AGL's board of directors are considered experienced (8.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.7%.


Top Shareholders

Company Information

ANGLE plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ANGLE plc
  • Ticker: AGL
  • Exchange: AIM
  • Founded: 2004
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: UK£88.932m
  • Shares outstanding: 172.68m
  • Website: https://www.angleplc.com

Number of Employees


Location

  • ANGLE plc
  • The Surrey Research Park
  • 10 Nugent Road
  • Guildford
  • Surrey
  • GU2 7AF
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AGLAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPMar 2004
ANPC.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMar 2004
DWVDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMar 2004
ANPC.YOTCPK (Pink Sheets LLC)SPONSONRED ADRUSUSDOct 2014

Biography

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. It develops and commercializes Parsortix cell separation system, which captures and harvests rare circulating tumor cells in cancer patient blood; and Ziplex multiplex analysis system that is used with the ovarian cancer clinical application and others. The company was founded in 2004 and is based in Guildford, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/07 20:41
End of Day Share Price2020/04/07 00:00
Earnings2019/10/31
Annual Earnings2019/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.